IDE-161

Other Medications

EU Experimental ES Not available 1 Clinical Trials

Description

IDE-161 is an experimental drug currently being studied in clinical trials for certain types of advanced solid tumors, including colorectal cancer. It is being investigated specifically in patients whose tumors have BRCA1/2 gene mutations or other problems with the homologous recombination pathway (a way cells repair DNA damage). The goal of the trials is to determine the safe dosage of IDE-161, how it affects the body, and if it shows any early signs of shrinking tumors. In some trials, IDE-161 is also being given together with pembrolizumab (an immunotherapy drug) to see if the combination is effective, particularly in endometrial cancer. It is important to remember that IDE-161 is not yet approved for treating colorectal cancer and is still in early-phase testing.

Mechanism of Action

IDE-161 is a PARG (poly(ADP-ribose) glycohydrolase) inhibitor. PARG is an enzyme involved in DNA repair. By inhibiting PARG, IDE-161 may disrupt the repair of DNA damage, particularly in cancer cells that rely heavily on this pathway, especially those with defects in the homologous recombination pathway like BRCA1/2 mutations. This disruption may lead to increased DNA damage and potentially kill the cancer cells. The specific mechanism and effectiveness are still being investigated in clinical trials.

Side Effects

As IDE-161 is an investigational drug in early-phase clinical trials (Phase 1) The full range and frequency of side effects are still being evaluated. The primary goal of Phase 1 trials is to assess safety and determine the maximum tolerated dose. Information about specific side effects experienced by patients in these trials is not yet widely available. Participants in the trials are closely monitored for any adverse events.

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT05787587 Phase 1
Active, not recruiting
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
United States

Quick Info

CategoryOther Medications
EU EMA StatusExperimental
ES Spain AccessNot available
Clinical Trials1
View Clinical Trials Back to Drug Glossary

Related Medications

Uracil
Other Medications
781 trials
Leucovorin
Other Medications
641 trials
Paclitaxel
Other Medications
54 trials
Cyclophosphamid
Other Medications
50 trials
Cyclophosphamide
Other Medications
49 trials
Trifluridine
Other Medications
48 trials

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.